The following table is representative of the significant expense categories regularly provided to the CODM when managing the Company’s single reporting segment. A reconciliation to the consolidated net loss for the years ended December 31, 2025, December 31, 2024 and December 31, 2023 is included in the table below:


	Year Ended
(in thousands)	December 31, 2025		December 31, 2024		December 31, 2023
Revenue:
Screening revenue	$	138,601	$	108,627	$	74,999
Development services revenue	8,571		16,968		18,106
Total revenue	147,172		125,595		93,105
Costs and operating expenses:
Cost of screening revenue (exclusive of amortization of intangible assets)(1)(2)	73,251		63,284		47,966
Cost of development services revenue(1)(2)	2,605		6,444		6,861
Compensation	231,188		314,042		311,375
Depreciation and intangible assets amortization expense	149,794		153,228		148,920
Stock-based compensation	56,021		84,130		95,265
Professional services	36,821		63,443		48,994
Clinical studies	28,012		43,890		54,590
Goodwill and intangible assets impairment	28,000		1,420,936		718,466
Cloud computing and information technology	25,019		30,233		31,868
Facilities	21,666		25,983		30,276
Laboratory supplies and research collaborations	12,802		41,341		41,863
Other segment expenses(3)	44,156		67,799		72,043
Total costs and operating expenses	709,335		2,314,753		1,608,487
Loss from Operations	(562,163)		(2,189,158)		(1,515,382)
Other income (expense):
Interest income	28,652		26,733		7,954
Other income (expense), net	(993)		64		(208)
Benefit from income taxes	126,153		135,356		41,951
Net Loss	$	(408,351)	$	(2,027,005)	$	(1,465,685)

(2) Cost of screening revenue (exclusive of amortization of intangible assets) and cost of development services revenue include $6.6 million, $4.8 million and $9.8 million of depreciation expense for the year ended December 31, 2025, December 31, 2024 and December 31, 2023.